REGN vs VRTX: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

VRTX has stronger fundamentals based on our AI analysis.

REGN
REGENERON PHARMACEUTICALS, INC.
A
80%
Confidence
VS
VRTX
VERTEX PHARMACEUTICALS INC / MA
A
81%
Confidence

REGN vs VRTX Fundamental Comparison

Metric REGN VRTX
Revenue $3.6B $3.0B
Net Income $727.2M $1.0B
Net Margin 20.2% 34.5%
ROE 2.3% 5.3%
ROA 1.8% 3.9%
Current Ratio 3.57x 3.02x
Debt/Equity 0.06x 0.01x
EPS $6.75 $4.02

Green = Better metric | Red = Weaker metric

View Full REGN Analysis →
View Full VRTX Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Top Rated Undervalued Growth Dividend

You Might Also Compare

REGN vs AAPL VRTX vs MSFT REGN vs GOOGL VRTX vs AMZN

REGN vs VRTX: Frequently Asked Questions

Is REGN or VRTX the better stock in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), VRTX has stronger fundamentals. REGN is graded A (80% confidence) while VRTX is graded A (81% confidence). This is not investment advice.

How does REGN compare to VRTX fundamentally?

REGENERON PHARMACEUTICALS, INC. has ROE of 2.3% vs VERTEX PHARMACEUTICALS INC / MA's 5.3%. Net margins are 20.2% vs 34.5% respectively.

Which stock pays higher dividends, REGN or VRTX?

REGN has a dividend yield of N/A or no dividend while VRTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in REGN or VRTX for long term?

For long-term investing, consider that REGN has a A grade with 80% confidence, while VRTX has a A grade with 81% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about REGN vs VRTX?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For REGN vs VRTX, the AI consensus favors VRTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.